Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform

DIANT Pharma's Antonio Costa, Ph.D., explains how DIANT Pharma’s tightly controlled, end-to-end adaptable production platform provides provides an ideal continuous manufacturing solution for achieving robust, scalable nucleic acid–LNP manufacturing.